HPLC in pharmaceutical analysis

Significance of the Topic

The purity of water is fundamental to pharmaceutical manufacture and high-performance liquid chromatography (HPLC) analysis. Water serves as a raw material, solvent and excipient in drug synthesis, formulation and quality control. Impurities in water can compromise active pharmaceutical ingredients (APIs), degrade chromatographic performance and lead to false or irreproducible analytical results. Regulatory agencies worldwide mandate strict water quality standards, so understanding water grades and their impact on HPLC is essential for reliable, compliant drug development and production.

Aims and Overview of the Article

This white paper reviews the role of water in pharmaceutical processes and HPLC workflows. It outlines current pharmacopeial requirements for water grades—Purified Water, Highly Purified Water and Water for Injections (WFI)—and describes their applications at different stages: as an excipient in final formulations, during API manufacture, for equipment cleaning and specifically for HPLC and dissolution testing. Key challenges, guidelines revisions and case studies on water-related chromatographic issues are also discussed.

Methodology and Instrumentation

The article examines pharmacopeia monographs (USP, Ph. Eur., JP), compares water quality parameters (conductivity, TOC, microbial limits) and reviews water purification technologies: distillation, reverse osmosis, ultrafiltration, electro-deionisation and nanofiltration. It uses case examples where bottled HPLC-grade water was compared to in-house ultrapure water on a C18 column with UV detection at 254 nm. Dissolution testing protocols, standardised vessels, degassing methods and sample analysis by HPLC are also described.

Main Results and Discussion

Recent revisions allow WFI production via non-distillation methods (reverse osmosis plus ultrafiltration) under Ph. Eur. and USP guidelines, reducing energy use and cost. Tables summarising water grades show limits for TOC (<500 ppb C for Purified Water), conductivity (<1.1 µS/cm for WFI) and bacterial counts. Poor water quality causes ghost peaks, baseline shifts, column blockages and compromised sensitivity. In one study, bottled HPLC water yielded large background peaks when pre-concentrated, while freshly produced ultrapure water did not. This highlights the superiority of dedicated purification systems for HPLC and QA/QC to ensure trace-level detection and reproducible results.

Benefits and Practical Applications of the Method

• Regulatory compliance: Meets USP and Ph. Eur. standards across all stages of drug production.
  
• Analytical reliability: Prevents chromatographic artefacts, protects column life and enhances sensitivity.
  
• Sustainability: Replaces energy-intensive distillation with efficient membrane-based purification.
  
• Operational cost savings: In-house systems reduce dependence on bottled water and limit waste.
  
• Quality assurance: Supports batch consistency, generic equivalence studies and dissolution testing for bioavailability assessments.
  

Future Trends and Potential Applications

Advances in real-time monitoring, digital water quality tracking and automated purification control will further strengthen compliance and reduce risk. Emerging membrane technologies promise higher throughput and lower fouling. Integration of HPLC with high-resolution mass spectrometry and ultra-high-pressure systems will raise purity demands, driving adoption of next-generation water systems. Enhanced analytics for chiral separations and biologics will also rely on ultrapure water quality.

Conclusion

Water purity is a cornerstone of pharmaceutical HPLC analysis and drug manufacturing. Adhering to updated pharmacopeial guidelines and employing robust in-house purification systems ensures accurate, reproducible and cost-effective analytical performance. By understanding water grades and maintaining stringent quality control, laboratories can safeguard patient safety and meet regulatory requirements.

References

1. Shuksith KS, Gupta NV. Water for pharmaceutical use. Int J Pharm Sci Rev Res. 2016;36(1):199–204.
2. USP 35, General Chapter <1231>. United States Pharmacopeial Convention; 2012.
3. European Pharmacopoeia 7th ed. EDQM; 2011.
4. Johnston A, Holt DW. Substandard drugs: a potential crisis for public health. Br J Clin Pharmacol. 2014;78(2):218–243.
5. Misiuk W. Role of assay methods in characterizing bulk pharmaceuticals. J Pharm Bioallied Sci. 2010;2(2):88–92.
6. Yamamoto C, Okamoto Y. Chiral Analysis. HPLC resolution using polysaccharide derivatives. Elsevier; 2006.
7. EMA. Guideline on the quality of water for pharmaceutical use. 2018.
8. McMaster MC. HPLC and Column Maintenance. In: LC/MS: A Practical User’s Guide. Wiley; 2005.
9. Nabulsi et al. Impact of water quality on laboratory testing. Lab Med. 2014;45(4):159–165.
10. NIH. Laboratory Water: Its Importance and Application. 2013.
11. ELGA LabWater. Type I Ultrapure Water Crucial for HPLC and UHPLC. Application Note.
12. CLSI. Preparation and Testing of Reagent Water in the Clinical Laboratory. 4th ed. 2006.
13. ELGA LabWater. Pure Labwater Guide: Overview of Purification Applications. 2019.
14. Anand O, Yu L, Conner D, Davit B. Dissolution Testing for Generic Drugs: An FDA Perspective. AAPS J. 2011;13(3):328–335.